Correspondence 0001493152-23-036756 from Propanc Biopharma, Inc. (PPCB)
Propanc Biopharma, Inc.
Date: Oct. 10, 2023 · CIK: 0001517681 · Accession: 0001493152-23-036756
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273953
Letter
Propanc Biopharma, Inc.
302, 6 Butler Street
Camberwell, VIC 3124
Australia
October 10, 2023
Via EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
F Street NE
Washington, D.C. 20549
Re: Propanc Biopharma, Inc.
Registration Statement on Form S-1, as amended
File No. 333-273953
Ladies and Gentlemen:
Propanc Biopharma, Inc. (the “Company”) hereby requests acceleration of the effectiveness of the above-referenced registration statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become effective on October 12, 2023, at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.
The Company understands that the Commission will consider this request for acceleration of the effective date of the above-referenced registration statement as a confirmation of the fact that the Company is aware of its responsibilities under the Securities Act and the Securities Exchange Act of 1934, as amended, as they relate to the proposed sale of the securities specified in the above-referenced registration statement.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Sullivan & Worcester LLP, by calling David E. Danovitch at (212) 660-3060. We also respectfully request that a copy of the written order from the Commission verifying the effective date and time of the Registration Statement be sent to Mr. Danovitch via email at ddanovitch@sullivanlaw.com.
Very
truly yours,
PROPANC
BIOPHARMA, INC.
Show Raw Text
CORRESP
1
filename1.htm
Propanc
Biopharma, Inc.
302,
6 Butler Street
Camberwell,
VIC 3124
Australia
October
10, 2023
Via
EDGAR
United
States Securities and Exchange Commission
Division
of Corporation Finance
100
F Street NE
Washington,
D.C. 20549
Re:
Propanc
Biopharma, Inc.
Registration
Statement on Form S-1, as amended
File
No. 333-273953
Ladies
and Gentlemen:
Propanc
Biopharma, Inc. (the “Company”) hereby requests acceleration of the effectiveness of the above-referenced registration
statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may
become effective on October 12, 2023, at 5:00 p.m., Eastern Time, or as soon thereafter as is practicable.
The
Company understands that the Commission will consider this request for acceleration of the effective date of the above-referenced registration
statement as a confirmation of the fact that the Company is aware of its responsibilities under the Securities Act and the Securities
Exchange Act of 1934, as amended, as they relate to the proposed sale of the securities specified in the above-referenced
registration statement.
Once
the Registration Statement is effective, please orally confirm the event with our counsel, Sullivan & Worcester LLP, by calling David
E. Danovitch at (212) 660-3060. We also respectfully request that a copy of the written order from the Commission verifying the effective
date and time of the Registration Statement be sent to Mr. Danovitch via email at ddanovitch@sullivanlaw.com.
Very
truly yours,
PROPANC
BIOPHARMA, INC.
By:
/s/
James Nathanielsz
James
Nathanielsz
Chief
Executive Officer